凝胶过滤与镍柱亲和纯化金葡菌α-溶血素重组蛋白的生物学特性比较

以在宿主菌株BL21(DE3)中成功表达的重组金黄色葡萄球菌α-溶血素蛋白为研究对象,分析比较通过凝胶过滤层析(Gel filtration chromatography)和镍柱亲和层析纯化试剂盒(Ni-NTA spin columns)纯化所得到的重组蛋白的蛋白含量和生物特性方面的差异.SDS-PAGE分析检测纯化产物,Bradford法测定蛋白含量,兔红细胞测定半数溶血效价,结果显示这2种方法得到的纯化产物在53 kD处均呈现单一清晰带,达电泳级纯度.与此同时,凝胶过滤对目的蛋白的纯化率为14.04%,蛋白含量为0.337 mg/mL,溶血活性为1519 HU/mg;镍柱亲和层析的纯化率为17.5%,蛋白含量为0.35 mg/mL.溶血活性为1463 HU/mg.由此可见,凝胶过滤得到的纯化产物在蛋白含量和蛋白活性方面丝毫不亚于镍柱亲和层析纯化试剂盒.     

化脓性链球菌溶血素O活性结构重组蛋白的制备

生物信息分析化脓性链球菌溶血素O(streptolysin O,Slo)蛋白结构表明,Slo蛋白除含有由461氨基酸残基组成的溶血活性结构域Thiol_cytolysin外,在N端还有一跨膜结构域。利用pET101-GENE蛋白表达系统,成功构建出表达具有Slo活性重组蛋白的重组子,采用镍柱亲和层析分离技术,纯化目的蛋白;纯化蛋白SDS-PAGE检测分析表明,重组蛋白与预测的溶血活性结构域的分子量相一致;溶血实验显示,纯化重组蛋白具有溶血活性。以纯化的重组蛋白为免疫原,对大鼠进行4次免疫,所获得免疫血清经 Elisa检测,抗Slo血清效价达到 1 ∶12 800;Western blot检测猪链球菌、马链球菌和化脓性链球菌中的链球菌溶血素结果显示,抗Slo多克隆抗体仅能与化脓性链球菌溶血素O发生反应,表明研究制备的化脓性链球菌溶血素O活性结构重组蛋白抗原具有较好的特异性,所制备的抗原Slo 可用于进一步开发抗链球菌溶血素O(ASO)试剂盒。     

嗜水气单胞菌十一碳焦磷酸合成酶XreF的原核表达及分离纯化

目的:构建嗜水气单胞菌十一碳焦磷酸合成酶XreF基因的原核表达载体,转入大肠杆菌诱导表达高活性的XreF蛋白。方法:从嗜水气单胞菌中提取基因组DNA,以基因组DNA为模板进行PCR扩增,构建pPROEX-HTaXreF重组载体,转入大肠杆菌BL21(DE3)表达目的蛋白;用镍离子亲和层析、离子交换层析、凝胶过滤层析分离纯化目的蛋白XreF;用分析型凝胶过滤柱检测XreF的聚集状态。结果:构建了重组载体pPROEX-HTa-XreF,测序结果与XerF基因编码序列一致;XreF蛋白在大肠杆菌中经IPTG诱导高效表达,纯化获得高浓度(17.5 mg/mL)、高纯度(96%以上)的XreF蛋白;分析型凝胶过滤结果显示,XreF在溶液中为单体,在镁离子存在的情况下为二聚体。结论:获得并纯化了在大肠杆菌中高效表达的嗜水气单胞菌XreF,镁离子可诱导XreF在溶液中由单体向二聚体转化。     

创伤弧菌溶细胞素融合蛋白重组、表达与细胞毒活性鉴定

研究重组创伤弧菌溶细胞素融合蛋白(rVvhA)诱导人脐静脉内皮细胞(human umbilical vein endothelial cells,human ECV304)凋亡的作用.诱导含pET-28a( )vvhA重组质粒的BL21大肠杆菌表达创伤弧菌溶细胞素融合蛋白,应用Ni2 亲和层析方法对rVvhA进行纯化:利用分步稀释加透析相结合的方法进行蛋白质复性;绵羊红细胞裂解试验对复性后的rVvhA进行溶血活性初步测定:MTT法检测rVvhA对人ECV304细胞的体外毒性作用:应用Hochest33342/PI活细胞荧光双染及流式细胞术分析rVvhA对人ECV304细胞诱导凋亡的影响.结果显示,用Ni2 -NTA His Band亲和层析柱纯化rVvhA纯度达88.6%左右;复性后的rVvhA有一定的溶血活性,其溶血活性具有时间.剂量依赖性;MTT结果显示rVvhA具有降低人ECV304细胞的存活率活性;浓度为2.0 HU/ml rVvhA作用人ECV304 12 h后,其诱导凋亡的活性高于对照组和浓度为0.5 HU/ml rVvhA处理组,具有剂量依赖性;浓度为2.0 HU/ml rVvhA处理组加用40μmol/L caspase全酶抑制剂(Z-VAD-FMK)后凋亡率较2.0 HU/ml rVvhA处理组有一定程度降低.rVvhA对人ECV304细胞具有诱导凋亡的生物学活性,推测诱导调亡途径可能与caspase家族有关.     

抗菌肽Cec4a的重组表达和抗菌活性研究*

目的:构建Cec4a的原核重组表达体系,通过诱导表达、酶切纯化获得重组蛋白,并检测产物的抗菌活性。方法:基于Cec4a的序列设计引物,克隆Cec4a基因的DNA片段。利用原核表达载体(pCold-SUMO)构建重组原核表达质粒,并将其转化到大肠杆菌C41(DE3)等感受态细胞,使用IPTG进行诱导表达。通过Ni-NTA亲和层析柱纯化,获得含有His-SUMO标签的重组Cec4a融合蛋白。在SUMO蛋白酶酶切后,再次使用Ni-NTA亲和层析纯化,得到目的蛋白,最后用鲍曼不动杆菌(ATCC19606)作为指示菌检测表达产物的抗菌活性。结果:成功构建pCold-SUMO-Cec4a原核表达质粒,测序分析其序列与预期结果一致。Cec4a融合蛋白表达量为42.8mg/L,纯化后的Cec4a重组蛋白对鲍曼不动杆菌的MIC为4 μg/mL。结论:通过原核表达,并经Ni-NTA亲和层析纯化,获得了具有抗菌活性的重组蛋白Cec4a,为研究Cec4a的生物活性、抗菌机制及应用奠定了基础。     

乙醛脱氢酶在乳酸乳球菌中的表达与纯化

目的:在乳酸乳球菌中重组表达乙醛脱氢酶(ALDH)。方法:合成毕赤酵母ALDH基因,PCR扩增后通过重组构建pNZ8048-ALDH表达载体,电转至乳酸乳球菌NZ9000感受态,Nisin诱导表达后经Ni柱亲和层析纯化ALDH蛋白,比色法测定酶活。结果:构建了pNZ8048-ALDH表达载体,在乳酸乳球菌NZ9000中实现了ALDH的重组表达,目的蛋白占全菌蛋白的17.2%,其中可溶性表达比例为53%,重组菌株ALDH活力为0.638 U/mL,亲和层析纯化蛋白纯度约70%,比活为0.48 U/mg。结论:在乳酸乳球菌中表达并纯化获得了有活性的ALDH。     

重组人脱氧核糖核酸酶Ⅰ的复性及活性鉴定

建立尿素梯度凝胶过滤复性重组人脱氧核糖核酸酶Ⅰ的方法。将诱导表达的重组人脱氧核糖核酸酶Ⅰ包涵体通过初步纯化后变性,然后在尿素梯度凝胶过滤色谱柱Sephadex G-75中复性,洗脱流速0.4 mL/min,复性完毕后透析除去小分子复性剂,使用琼脂糖电泳法检验其有活性后,再用单向酶扩散法测定其酶活力为655.8 U/mg,复性得率为83.7%。最后通过LC-ESI-MS/MS从氨基酸序列组成上证明复性产物是重组人脱氧核糖核酸酶Ⅰ。结果表明,建立的方法能成功用于复性变性的重组人脱氧核糖核酸酶Ⅰ包涵体蛋白,获得了可用于结构和功能研究的具有生物学活性的重组人脱氧核糖核酸酶Ⅰ。     

重组人促性腺激素释放激素及导肽的分离纯化与活性分析

对含重组人促性腺激素释放激素(GnRH)及导肽(LEP)的工程菌株进行诱导表达,分离纯化GnRH/LEP并进行生物学活性分析.工程菌IPTG诱导,收获的菌体经超声破碎后,裂解液用Glutathione-Sepharose 4B亲和层析纯化GST-GnRH/LEP融合蛋白,经CNBr裂解、Sephadex G-25柱脱盐、QAE-Sepharose FF阴离子交换柱层析和RP-C18柱脱盐,得到纯度大于98%的重组GnRH/LEP.Western blot表明表达产物均具有GrRH抗原特异性.生物学活性分析表明:该表达产物可促进小鼠次级卵泡向成熟卵泡发育,可提高其血清中E2含量.     

草鱼生长激素单抗免疫亲和柱的制备及初步应用

用纯化的草鱼生长激素单克隆抗体偶联到CNBr活化的Sepharose4B凝胶上,制成约10ml的亲和层析柱．用该柱一步纯化了重组鲤鱼生长激素基因的表达产物．偶联有13．65mg单克隆抗体的亲和柱一次可纯化得到约0．7mg重组鲤鱼生长激素．酶联免疫受体测定表明它具有强烈的生物学活性,SDS－PAGE表明它为单一蛋白带,分子量约为22000．     

人SDF-1α的原核表达、纯化及对小鼠骨髓造血的研究

目的:构建人SDF-1α原核表达载体,进行诱导表达,纯化并研究其对骨髓造血的作用。方法:克隆人SDF-1α成熟肽序列到原核表达载体pET28a( )中,在大肠杆菌BL21(DE3)中进行诱导表达,用阴离子交换柱Sepharose Q纯化目的蛋白,并检测重组蛋白的活性和内毒素含量。用纯化的蛋白注射小鼠进行药效学研究。结果:用此原核表达系统得到纯度95%以上的重组蛋白,浓度达到0．67mg/mL,产物内毒素含量低于1EU/ug,且具有体外促小鼠T细胞趋化活性。重组人SDF-1α以125ug/kg/day的剂量连续给药可以引起正常小鼠骨髓细胞升高。结论:重组人SDF-1α可以促进小鼠骨髓造血作用。     

金黄色葡萄球菌a-溶血素亚单位疫苗在小白鼠模型的免疫效力评价

目的:以小白鼠为试验模型,检测金黄色葡萄球菌α 溶血素基因工程蛋白单位疫苗的抗体效价水平和免疫保护力,初步评价此亚单位疫苗的免疫效力。方法:Bradfrod法对目的蛋白进行蛋白含量测定,Geoffroy法测定目的蛋白半数溶血效价和活性,建立ELISA方法测定抗体效价,并且通过攻毒得出疫苗免疫保护力。结果:纯化的目的蛋白在53kDa处显示单一条带,蛋白含量为0.1278mg/ml;溶血比活为8012.5HU/mg;所有试验小鼠在首免一周后采集的血清中都检测到了特异性抗体,而抗体效价开始时呈逐渐上升趋势,达最高值后随时间延长逐渐降低。结论:纯化的目的蛋白达到电泳级纯度,且依然保持良好的黏附活性,蛋白疫苗作用机体产生的抗体水平符合抗体消长规律。     

血管性血友病因子裂解蛋白酶的稳定表达及其活性检测

本研究旨在得到重组的血管性血友病因子裂解蛋白酶(ADAMTS13),进一步研究其在血栓止血中的作用。利用脂质体将编码ADAMTS13全长序列的重组质粒pSecTag-ADAMTS13转染Hela细胞,用潮霉素(Hygromycin-B)筛选得到阳性克隆细胞株,并扩大培养,收集上清。利用Ni-NTA琼脂糖柱、梯度咪唑淋洗法纯化蛋白,SDS-PAGE和Westernblotting鉴定纯化产品纯度和免疫学活性,采用GST-His双抗夹心法测定蛋白剪切活性。结果显示,成功获得一株能恒定分泌重组ADAMTS13蛋白的细胞株ADAMTS2-4,每1L培养上清可纯化得到5.8mg重组蛋白。Western blotting结果显示,ADAMTS13多抗能与重组蛋白在190kDa处显单一条带,并且蛋白具有6.4U/mL的剪切活性(每毫升正常人混合血浆中ADAMTS13活性为1U)。重组蛋白具有较好的免疫原活性和酶活性,为进一步研究ADAMTS13作用机理和运用奠定了良好的基础。     

蜂毒素分子的改造及其基因在毕赤酵母中的表达

为获得保留有抗菌活性而降低溶血作用的蜂毒素,对蜂毒素的分子结构进行了改造。将第5位的Val变为Arg,第15位Ala变为Arg,删除了第16位的Leu。用PCR技术获得了改造后的蜂毒素基因,将其克隆入酵母表达载体pPICZa-A,获得重组表达质粒pPICZa-A-MEA。该质粒转化毕赤酵母菌GS115,甲醇诱导下表达,发酵上清液经抑菌活性、溶血活性测定及亲和层析纯化,结果表明,蜂毒素基因成功地在毕赤酵母中表达,经改造后表达的蜂毒素保留了抗菌活性且溶血活性显著降低,经纯化后用Bradford法测定表达蜂毒素的含量约为0.29mg／ml。     

Expression and characterization of HlyX hemolysin from Leptospira interrogans serovar Copenhageni: potentiation of hemolytic activity by LipL32

The HlyX, a putative hemolysin identified from the Leptospira genomes, was cloned, expressed in Escherichia coli, purified, and its hemolytic activity was confirmed. Mouse polyclonal antiserum against the recombinant HlyX recognized HlyX-related antigens in a panel of Leptospira species extracts and it was also able to abolish the hemolytic activity of HlyX. A mixture of HlyX and LipL32, a known hemolysin from Leptospira, induced hemolysis in a synergistic way that was fully inhibited by antiserum against either protein. Moreover, sera from patients with leptospirosis also recognized the recombinant HlyX, showing that it is presented to the host immune system during Leptospira infection.     

High-level expression of the Listeria monocytogenes listeriolysin O in Escherichia coli and preliminary characterization of the purified protein

Listeriolysin O (LLO) is a cholesterol-binding sulfhydryl-activated hemolysin encoded by Listeria monocytogenes hlyA gene. After analyzing the nucleotide coding sequence of this gene from the ATCC 9525 L. monocytogenes strain, we cloned it in a pET vector for expression in Escherichia coli. Thanks to the optimization of the induction protocol, we achieved a high-level LLO synthesis (about 10% of total cell proteins) in hemolytically active form. The expressed hemolysin was then purified to homogeneity, as revealed by SDS-PAGE and Western blot analysis, by a hydroxyapatite adsorption chromatography, followed by an SP Sepharose ion-exchange chromatography. The recombinant protein showed the same properties determined for LLO purified from L. monocytogenes cultures and the characteristics of the sulfhydryl-activated toxins such as inactivation by oxidation and by reaction with cholesterol. By a combination of the pET expression system and the simple purification method, we obtained a significant amount of toxin (4.5 mg/litre cell culture) in a hemolytically active form (1.25 x 10(6)HU/mg protein). This procedure can solve the problem of LLO isolation from L. monocytogenes cultures, which is a difficult task, mainly owing to the low levels of toxin released in the culture media. The recombinant hemolysin, purified in sufficient quantities, could be very useful for structural studies and for diagnostic and pharmaceutical applications.     

Purification and biological characterization of bacterially expressed recombinant buffalo prolactin

Recombinant prolactin (PRL) from water buffalo (Bubalus bubalis) has been cloned and expressed in a prokaryotic expression system. The hormone was also successfully refolded into a biologically active form. Total RNA was purified from buffalo pituitaries and the buPRL cDNA was synthesized using primers designed on bovine PRL sequence. This prolactin cDNA was cloned in a pET 28a vector and expressed in Escherichia coli strain BL21(DE3)pLysS. Most of the expressed protein was present as insoluble inclusion bodies. The inclusion bodies were solubilized and buPRL was purified by Ni-NTA column. The purified protein was refolded by gradually decreasing the concentration of denaturant during dialysis. Total yield of the refolded and soluble prolactin was 22?mg/L from 100?mL bacterial culture in LB medium. The recombinant prolactin was as active as native prolactin in stimulating growth of Nb2 lymphoma cells.     

Extracellular expression and single step purification of recombinant Escherichia coli L-asparaginase II

L-Asparaginase (isozyme II) from Escherichia coli is an important therapeutic enzyme used in the treatment of leukemia. Extracellular expression of recombinant asparaginase was obtained by fusing the gene coding for asparaginase to an efficient pelB leader sequence and an N-terminal 6x histidine tag cloned under the T7lac promoter. Media composition and the induction strategy had a major influence on the specificity and efficiency of secretion of recombinant asparaginase. Induction of the cells with 0.1 mM IPTG at late log phase of growth in TB media resulted in fourfold higher extracellular activity in comparison to growing the cells in LB media followed by induction during the mid log phase. Using an optimized expression strategy a yield of 20,950 UI/L of recombinant asparaginase was obtained from the extracellular medium. The recombinant protein was purified from the culture supernatant in a single step using Ni-NTA affinity chromatography which gave an overall yield of 95 mg/L of purified protein, with a recovery of 86%. This is approximately 8-fold higher to the previously reported data in literature. The fluorescence spectra, analytical size exclusion chromatography, and the specific activity of the purified protein were observed to be similar to the native protein which demonstrated that the protein had folded properly and was present in its active tetramer form in the culture supernatant.